Avidity Biosciences Shares Plummets 10.10 as $220M Volume Ranks 489th Amid $690M Capital Raise for RNA Therapies

On September 15, 2025, , , . The stock ranked 489th in trading activity among listed equities.

The company announced the completion of an upsized public offering, , . All shares were sold by Avidity, with Leerink Partners, J.P. Morgan, and other underwriters managing the deal. Funds will advance three late-stage clinical programs, build commercial inventory, expand infrastructure, and support general operations. The offering utilized a pre-filed SEC registration statement.

Avidity’s targets RNA delivery for rare neuromuscular and cardiovascular diseases. . The firm remains on track for a 2025 (BLA) for del-zota, its DMD44 therapy, .

The currently supports single-ticker analysis, limiting multi-asset strategies. To proceed, . Avidity’s recent capital raise underscores its focus on advancing AOC-based therapies, with clinical and regulatory milestones expected to drive near-term activity.